Dr. Zaheed Husain is a cancer immunologist. He recently retired from the Laboratory of Immunobiology in the Division of Interdisciplinary Medicine and Biotechnology at Harvard Medical School, Beth Israel Hospital, in Boston, MA and was a faculty with the school’s Department of Medicine. He previously served for nearly a decade as the principal scientist and team leader in the immunology and oncology section of Wyeth Pharmaceuticals. At Wyeth, Dr. Husain was responsible for the discovery of EKI-785, a small molecule inhibitor of head and neck cancers; he subsequently led a research group of biologists and chemists responsible for filing the new drug with the Federal Drug Administration. He is a member of the American Association for the Advancement of Science (since 1989), has over 75 publications in peer-reviewed scientific journals and holds multiple patents. Dr. Husain earned his Ph.D. in Molecular Biology and Biochemistry from New York University and trained as a post-doctoral fellow in the Department of Pathology at Harvard and Dana-Farber Cancer Institute.